Nivolumab Is China ’s First Approved Immuno-Oncology Drug

In CheckMate -078, nivolumab yielded superior OS compared with docetaxel in previously treated NSCLC, regardless of PD-L1 expression and tumor histology.

Source: CancerNetwork - June 27, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news